NO20054546D0 - Kinazoliner nyttige som modulatorer av ionekanaler - Google Patents
Kinazoliner nyttige som modulatorer av ionekanalerInfo
- Publication number
- NO20054546D0 NO20054546D0 NO20054546A NO20054546A NO20054546D0 NO 20054546 D0 NO20054546 D0 NO 20054546D0 NO 20054546 A NO20054546 A NO 20054546A NO 20054546 A NO20054546 A NO 20054546A NO 20054546 D0 NO20054546 D0 NO 20054546D0
- Authority
- NO
- Norway
- Prior art keywords
- kinazolines
- modulators
- useful
- ion channels
- channels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45145803P | 2003-03-03 | 2003-03-03 | |
US46379703P | 2003-04-18 | 2003-04-18 | |
PCT/US2004/006451 WO2004078733A1 (en) | 2003-03-03 | 2004-03-03 | Quinazolines useful as modulators of ion channels |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054546D0 true NO20054546D0 (no) | 2005-10-03 |
NO20054546L NO20054546L (no) | 2005-11-25 |
Family
ID=32965550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054546A NO20054546L (no) | 2003-03-03 | 2005-10-03 | Kinazoliner anvendelige som modulatorer av ionekanaler |
Country Status (21)
Country | Link |
---|---|
US (2) | US7678802B2 (no) |
EP (1) | EP1608632B1 (no) |
JP (1) | JP5247027B2 (no) |
KR (1) | KR20050108379A (no) |
AR (1) | AR044502A1 (no) |
AT (1) | ATE453629T1 (no) |
AU (1) | AU2004217891B2 (no) |
BR (1) | BRPI0408026A (no) |
CA (1) | CA2517844A1 (no) |
CL (1) | CL2004000409A1 (no) |
DE (1) | DE602004024873D1 (no) |
ES (1) | ES2338553T3 (no) |
HK (1) | HK1088314A1 (no) |
IL (1) | IL170636A (no) |
NO (1) | NO20054546L (no) |
NZ (1) | NZ542664A (no) |
PE (1) | PE20041059A1 (no) |
RU (1) | RU2378260C2 (no) |
TW (1) | TW200426147A (no) |
UY (1) | UY28215A1 (no) |
WO (1) | WO2004078733A1 (no) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713983B2 (en) * | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
US7763627B2 (en) * | 2003-04-09 | 2010-07-27 | Exelixis, Inc. | Tie-2 modulators and methods of use |
WO2005007672A2 (en) * | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
WO2005046698A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
US7928107B2 (en) * | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
US7718658B2 (en) * | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
ATE435214T1 (de) * | 2004-09-02 | 2009-07-15 | Vertex Pharma | Als ionenkanalmodulatoren geeignete chinazoline |
US8283354B2 (en) * | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
PL382927A1 (pl) * | 2004-12-17 | 2008-02-04 | Vertex Pharmaceuticals Incorporated | Sposoby wytwarzania 4-aminochinazolin |
US8252806B2 (en) | 2005-03-14 | 2012-08-28 | Neurosearch A/S | Potassium channel modulating agents and their medical use |
US7683066B2 (en) * | 2005-05-20 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Isoquinolines useful as modulators of ion channels |
FR2891829A1 (fr) * | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
MX2008006303A (es) | 2005-11-14 | 2009-02-26 | Vertex Pharma | Quinazolinas de utilidad como moduladores de canales ionicos regulados por voltaje. |
CA2630617C (en) | 2005-11-23 | 2014-03-25 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
EP1968968A1 (en) * | 2005-12-21 | 2008-09-17 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
CA2652307A1 (en) * | 2006-04-10 | 2007-10-18 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
JP2009534458A (ja) | 2006-04-26 | 2009-09-24 | キャンサー・リサーチ・テクノロジー・リミテッド | アミノ−エチル−アミノ−アリール(aeaa)化合物およびそれらの使用 |
CA2654842A1 (en) | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
US8541428B2 (en) * | 2006-08-22 | 2013-09-24 | Technion Research And Development Foundation Ltd. | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof |
AU2007304195A1 (en) * | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
CN101547922B (zh) | 2006-10-04 | 2012-06-20 | 辉瑞产品公司 | 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物 |
AU2007328336B2 (en) * | 2006-12-01 | 2014-04-17 | President And Fellows Of Harvard College | Compounds and methods for enzyme-mediated tumor imaging and therapy |
CA2681516A1 (en) * | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of janus kinases |
HUE034298T2 (en) * | 2007-05-17 | 2018-02-28 | Helperby Therapeutics Ltd | Use of 4- (Pyrrolidin-1-yl) quinoline derivatives to kill clinically latent microorganisms |
WO2008157500A1 (en) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
US20090023773A1 (en) * | 2007-06-27 | 2009-01-22 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
EP2227460B1 (en) * | 2007-10-24 | 2012-06-20 | Cancer Research Technology Limited | Therapeutic oxy-phenyl-aryl compounds and their use |
ES2404076T3 (es) * | 2008-11-14 | 2013-05-23 | F. Hoffmann-La Roche Ag | Derivados quinazolina como antagonistas del receptor de NK3 |
CN102459249A (zh) | 2009-05-22 | 2012-05-16 | 埃克塞里艾克西斯公司 | 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用与制造方法 |
WO2010135568A1 (en) * | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and their use to treat cancer |
WO2010151595A1 (en) * | 2009-06-26 | 2010-12-29 | Schering Corporation | Pyrrolo-benzo-1,4-diazines useful as sodium channel blockers |
US20110053916A1 (en) | 2009-08-14 | 2011-03-03 | Vertex Pharmaceuticals Incorporated | Pyrimidine compounds as tuberculosis inhibitors |
LT3575288T (lt) | 2009-09-03 | 2021-12-10 | Bristol-Myers Squibb Company | Chinazolinai kaip kalio jonų kanalų inhibitoriai |
AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
US9045435B2 (en) | 2010-10-05 | 2015-06-02 | Purdue Pharma, L.P. | Quinazoline compounds as sodium channel blockers |
DK2835131T3 (en) * | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
WO2013070852A2 (en) * | 2011-11-08 | 2013-05-16 | Emory University | Compounds and compositions used to epigenetically transform cells and methods related thereto |
WO2013143319A1 (zh) * | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及其用途 |
CN104395298A (zh) * | 2012-06-22 | 2015-03-04 | 住友化学株式会社 | 稠合杂环化合物 |
US20150259649A1 (en) | 2012-11-08 | 2015-09-17 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
MX2015007921A (es) | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
WO2014143609A1 (en) * | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
US9242966B2 (en) * | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
CA3109285A1 (en) * | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN103755649A (zh) * | 2013-12-31 | 2014-04-30 | 李增 | 一种喹唑啉衍生物及其作为血管生成抑制剂的应用 |
JP6577479B2 (ja) * | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Nav チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
JP6498695B2 (ja) | 2014-04-23 | 2019-04-10 | テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド | キナゾリン骨格系の化合物、医薬組成物およびその使用方法 |
CN107427506A (zh) * | 2014-10-14 | 2017-12-01 | 拉霍拉敏感及免疫学研究所 | 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途 |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10087148B2 (en) * | 2014-12-05 | 2018-10-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health | Quinazolines as biogenic amine transport modulators |
JP2017537946A (ja) | 2014-12-11 | 2017-12-21 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての置換複素環 |
CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
CA2974078A1 (en) * | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
WO2017075222A1 (en) * | 2015-10-30 | 2017-05-04 | Lieber Institute For Brain Development | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity |
KR102327053B1 (ko) * | 2017-03-16 | 2021-11-17 | 기초과학연구원 | 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도 |
EP3619210A4 (en) | 2017-05-01 | 2020-12-02 | Sanford Burnham Prebys Medical Discovery Institute | LOW MOLECULAR PROTEIN TYROSINE PHOSPHATASE (LMPTP) INHIBITORS AND USES THEREOF |
MX2020001261A (es) * | 2017-08-02 | 2020-08-17 | Univ Northwestern | Compuestos de pirimidina fusionada sustituida y usos de los mismos. |
WO2019152724A1 (en) * | 2018-02-02 | 2019-08-08 | Prozyme, Inc. | Methods and kits for using blocked 2-aa for glycan analysis |
EP3827001A1 (en) | 2018-07-26 | 2021-06-02 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
KR20210111787A (ko) * | 2019-01-03 | 2021-09-13 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질 |
CN114401935B (zh) * | 2019-12-14 | 2024-04-05 | 上海市东方医院(同济大学附属东方医院) | 离子通道拮抗剂/阻断剂及其用途 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE119051C (no) | ||||
NL292083A (no) * | 1962-09-18 | |||
US3340260A (en) * | 1962-12-03 | 1967-09-05 | Ciba Geigy Corp | 4-amino-pyrimidines |
GB1199768A (en) * | 1966-10-31 | 1970-07-22 | Pfizer & Co C | Nitrogen Heterocycles and process for their preparation |
US3637693A (en) | 1968-07-12 | 1972-01-25 | Du Pont | Hydroxyarylquinazolines and their use as uv-absorbers |
US3705898A (en) * | 1970-01-26 | 1972-12-12 | Morton Norwich Products Inc | Certain 4 - amino - 2-(5-nitro-2-thienyl) quinazolines and the intermediate 4 - chloro-(5 - nitro-2-thienyl)quinazolines therefor |
DE2121031A1 (en) * | 1971-04-29 | 1972-11-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Base-substd quinazolines - thrombocyte aggregation inhibitors |
US3819628A (en) * | 1972-07-31 | 1974-06-25 | Sandoz Ag | 2-phenyl-4-substituted amino-quinazolines and nitrates thereof |
CH612432A5 (no) * | 1975-05-12 | 1979-07-31 | Sandoz Ag | |
US4306065A (en) | 1979-12-19 | 1981-12-15 | A. H. Robins Company, Incorporated | 2-Aryl-4-substituted quinazolines |
US4377582A (en) | 1979-12-19 | 1983-03-22 | A. H. Robins Company, Inc. | 2-Phenyl-4-[cis-2,5-dimethyl-4-(2-pyridinyl)-1-piperazinyl]quinazoline |
JPS56120768A (en) * | 1980-01-31 | 1981-09-22 | Ciba Geigy Ag | Color developing quinazoline compound |
JPS58172379A (ja) | 1982-04-02 | 1983-10-11 | Showa Denko Kk | 新規なキナゾリン誘導体 |
CN1048018C (zh) * | 1993-06-17 | 2000-01-05 | 株式会社大塚制药工场 | 膦酸二酯衍生物 |
JPH083144A (ja) * | 1994-06-21 | 1996-01-09 | Chugai Pharmaceut Co Ltd | キナゾリン及びキノリン誘導体 |
GB2295387A (en) * | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
FR2751656B1 (fr) * | 1996-07-24 | 1998-10-16 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
CN1169795C (zh) | 1996-10-01 | 2004-10-06 | 协和发酵工业株式会社 | 环胺取代的含氮杂环化合物及其组合物 |
JP2002514197A (ja) | 1996-12-13 | 2002-05-14 | イーライ・リリー・アンド・カンパニー | Psaの酵素活性の阻害物質 |
JP3989102B2 (ja) * | 1997-10-02 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合ピリジン誘導体 |
DE19747063A1 (de) * | 1997-10-24 | 1999-04-29 | Basf Ag | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
DE19756388A1 (de) * | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
JP3018185B1 (ja) * | 1999-02-12 | 2000-03-13 | 工業技術院長 | キナゾリン誘導体又はその塩の製造方法 |
JP2001068452A (ja) * | 1999-08-26 | 2001-03-16 | Matsushita Electric Ind Co Ltd | 回路パターン形成済シリコン基板のエッチング装置およびエッチング方法 |
JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
ES2156574B1 (es) * | 1999-11-18 | 2002-02-01 | Vita Invest Sa | Nuevos derivados de tiazolidindiona como agentes antidiabeticos |
AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
JP4101053B2 (ja) | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
AU2001293817A1 (en) | 2000-09-20 | 2002-04-02 | Merck Patent Gmbh | 4-amino-quinazolines |
WO2003097615A1 (en) | 2002-05-17 | 2003-11-27 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS |
AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
DE602004014347D1 (de) * | 2003-03-12 | 2008-07-24 | Millennium Pharm Inc | Chinazolin-derivate als tgf-beta-inhibitoren |
TWI289217B (en) * | 2004-07-16 | 2007-11-01 | Hon Hai Prec Ind Co Ltd | Light guide plate |
US7928107B2 (en) * | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
US7718658B2 (en) | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
US8283354B2 (en) | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
PL382927A1 (pl) | 2004-12-17 | 2008-02-04 | Vertex Pharmaceuticals Incorporated | Sposoby wytwarzania 4-aminochinazolin |
MX2008006303A (es) | 2005-11-14 | 2009-02-26 | Vertex Pharma | Quinazolinas de utilidad como moduladores de canales ionicos regulados por voltaje. |
-
2004
- 2004-03-02 CL CL200400409A patent/CL2004000409A1/es unknown
- 2004-03-03 NZ NZ542664A patent/NZ542664A/en unknown
- 2004-03-03 AU AU2004217891A patent/AU2004217891B2/en not_active Ceased
- 2004-03-03 WO PCT/US2004/006451 patent/WO2004078733A1/en active Application Filing
- 2004-03-03 UY UY28215A patent/UY28215A1/es not_active Application Discontinuation
- 2004-03-03 AR ARP040100670A patent/AR044502A1/es not_active Application Discontinuation
- 2004-03-03 KR KR1020057016287A patent/KR20050108379A/ko not_active Application Discontinuation
- 2004-03-03 DE DE602004024873T patent/DE602004024873D1/de not_active Expired - Lifetime
- 2004-03-03 CA CA002517844A patent/CA2517844A1/en not_active Abandoned
- 2004-03-03 TW TW093105557A patent/TW200426147A/zh unknown
- 2004-03-03 ES ES04716887T patent/ES2338553T3/es not_active Expired - Lifetime
- 2004-03-03 US US10/792,688 patent/US7678802B2/en not_active Expired - Lifetime
- 2004-03-03 AT AT04716887T patent/ATE453629T1/de active
- 2004-03-03 PE PE2004000236A patent/PE20041059A1/es not_active Application Discontinuation
- 2004-03-03 BR BR0408026-2A patent/BRPI0408026A/pt not_active IP Right Cessation
- 2004-03-03 JP JP2006509028A patent/JP5247027B2/ja not_active Expired - Fee Related
- 2004-03-03 RU RU2005130486/04A patent/RU2378260C2/ru not_active IP Right Cessation
- 2004-03-03 EP EP04716887A patent/EP1608632B1/en not_active Expired - Lifetime
-
2005
- 2005-09-04 IL IL170636A patent/IL170636A/en not_active IP Right Cessation
- 2005-10-03 NO NO20054546A patent/NO20054546L/no not_active Application Discontinuation
-
2006
- 2006-08-02 HK HK06108587.6A patent/HK1088314A1/xx not_active IP Right Cessation
-
2010
- 2010-01-15 US US12/688,163 patent/US8343980B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ542664A (en) | 2009-03-31 |
IL170636A (en) | 2012-08-30 |
RU2378260C2 (ru) | 2010-01-10 |
AU2004217891B2 (en) | 2011-06-23 |
AU2004217891A1 (en) | 2004-09-16 |
WO2004078733A1 (en) | 2004-09-16 |
EP1608632B1 (en) | 2009-12-30 |
UY28215A1 (es) | 2004-09-30 |
DE602004024873D1 (de) | 2010-02-11 |
TW200426147A (en) | 2004-12-01 |
CA2517844A1 (en) | 2004-09-16 |
ATE453629T1 (de) | 2010-01-15 |
AR044502A1 (es) | 2005-09-14 |
JP5247027B2 (ja) | 2013-07-24 |
US7678802B2 (en) | 2010-03-16 |
ES2338553T3 (es) | 2010-05-10 |
JP2006522119A (ja) | 2006-09-28 |
BRPI0408026A (pt) | 2006-02-07 |
RU2005130486A (ru) | 2006-05-10 |
US20110021495A1 (en) | 2011-01-27 |
HK1088314A1 (en) | 2006-11-03 |
US20040248890A1 (en) | 2004-12-09 |
US8343980B2 (en) | 2013-01-01 |
EP1608632A1 (en) | 2005-12-28 |
CL2004000409A1 (es) | 2005-01-07 |
KR20050108379A (ko) | 2005-11-16 |
PE20041059A1 (es) | 2005-02-07 |
NO20054546L (no) | 2005-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054546D0 (no) | Kinazoliner nyttige som modulatorer av ionekanaler | |
ZA200709961B (en) | Bicyclic derivatives as modulators of ion channels | |
DK1608624T3 (da) | 6-alkyl eller -alkenyl-4-aminopicolinater som herbicider | |
ATE456558T1 (de) | Gabanerge modulatoren | |
HK1119433A1 (en) | Indane derivatives as modulators of ion channels | |
DK1735286T3 (da) | Tetrahydroindazoler som cannabinoidmodulatorer | |
NO20054790D0 (no) | Anvendelse av B7-113 som et immunoregulatorisk middel | |
ECSP066436A (es) | Compuestos heterociclicos fusionados | |
ZA200805338B (en) | Heterocyclic derivatives as modulators of ion channels | |
ATE520261T1 (de) | Kopfhörer | |
DK1699797T3 (da) | Pyrrolotriazinforbindelser som kinasehæmmere | |
DE502004010304D1 (de) | Abdichtung | |
ATE540033T1 (de) | Als modulatoren von spannungsgesteuerten ionenkanälen geeignete chinazoline | |
DK2447252T3 (da) | Theramuteinmodulatorer | |
IS8292A (is) | Ný efnasambönd | |
NO20035183D0 (no) | 5-substituerte-2-arylpyridiner som CRF1 modulatorer | |
DE602004018247D1 (de) | Modulator | |
DK1581307T3 (da) | Irs modulatorer | |
FI20030099A (fi) | Momenttiohjatusti toimiva jarru | |
NO20024880L (no) | Sammensetning inneholdende fosfat | |
NO20033191D0 (no) | Fargemodulator | |
FR2862871B1 (fr) | Composition cosmetique anti-pollution | |
ATE357495T1 (de) | Rote bleichmittel | |
DE50301669D1 (de) | Dichtring | |
NO20030435D0 (no) | Optisk modulator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |